OpenScience.ink

2 weeks ago • Current medical research and opinion

Improved care and treatment results for obesity and knee arthritis in primary careAdvances in disease management and treatment outcomes for obesity and knee osteoarthritis in primary care practice.

Article

2 weeks ago • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Using Low-Dose Tirzepatide in Older Adults with Type 2 Diabetes: Treatment Continuation, Blood Sugar Benefits, and Simplified Care in Real LifeClinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort.

Article

2 weeks ago • Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Removing Intestinal MSTN May Increase GLP-1 Release by Changing SGLT1 FunctionLoss of Intestinal MSTN Promotes GLP-1 Secretion Through SGLT1 Palmitoylation.

🥈 Top 2% JournalArticle

2 weeks ago • Annals of Indian Academy of Neurology

Early Treatment with GLP-1 Receptor Agonists in Acute Stroke and High-Risk Mini-Stroke: A Review of Randomized TrialsEarly GLP-1 Receptor Agonist Therapy in Acute Ischemic Stroke and High-Risk Transient Ischemic Attack: A Systematic Review and Meta-analysis of Randomized Trials.

📖 Top 50% JournalArticle

2 weeks ago • The journal of knee surgery

Using GLP-1 Receptor Agonists Before Knee Replacement Surgery is Linked to Lower Risk of Heart Attack and Blood Clots After SurgeryGLP-1 Receptor Agonist Use Before Total Knee Arthroplasty is Associated With Lower Postoperative MI, DVT, and VTE Rates.

📖 Top 20% JournalArticle

2 weeks ago • Molecular aspects of medicine

How Type 2 Diabetes Medicines May Affect Cancer TreatmentType 2 diabetes medications and their implications for cancer treatment: A comprehensive review.

🥉 Top 5% JournalArticle

2 weeks ago • Diabetes, obesity & metabolism

Treatment habits and weight changes before and after tirzepatide price rise in over one million UK adults paying for their own obesity careReal-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.

Article

3 weeks ago • Diabetes, obesity & metabolism

GLP-1 Receptor Agonist Treatment Linked to Lower Risk of Foot Amputation in Adults with Type 2 Diabetes and Foot Ulcers Without Diagnosed Artery DiseaseGLP-1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis-Generating Real-World Cohort Study.

Article

3 weeks ago • Diabetologia

Effectiveness and safety of HRS-7535, a new oral drug that activates blood sugar control receptors, in people with type 2 diabetes not well managed by metformin and SGLT2 inhibitors: a multicenter, randomized, double-blind, placebo-controlled Phase II trialEfficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial.

🥈 Top 2% JournalArticle

3 weeks ago • AME case reports

Severe iron deficiency anemia despite iron treatment linked to semaglutide use: a case reportWhere did the iron go?-a case report of a patient with severe iron deficiency anemia despite parenteral and oral iron supplementation due to semaglutide application.

Case Reports

3 weeks ago • JAMA network open

Reported Side Effects in Social Media Users Taking Unapproved RetatrutideSelf-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.

🥈 Top 2% JournalArticle

3 weeks ago • Aesthetic surgery journal. Open forum

How Nutritional Deficiencies Caused by Glucagon-Like Peptide-1 Receptor Agonists May Affect Skin Health: A Guide for Aesthetic PractitionersThe Impact of Glucagon-Like Peptide-1 Receptor Agonist-Induced Nutritional Deficiencies on Skin Health: A Narrative Review With a Proposed Framework for the Aesthetic Practitioner.

Article

3 weeks ago • Acta gastroenterologica Latinoamericana

Digestive Side Effects of Drugs That Activate the Glucagon-Like Peptide-1 Receptor: A Complete ReviewGlucagon-Like Peptide-1 Receptor Agonist and Gastrointestinal Adverse Effects: A Comprehensive Review.

Article

3 weeks ago • PRiMER (Leawood, Kan.)

Blood Sugar Changes Linked to Shortages of GLP-1 Medicines in Type 2 DiabetesGlycemic Outcomes Associated With GLP-1 Receptor Agonist Shortages in Type 2 Diabetes.

Article

3 weeks ago • Frontiers in pharmacology

Side effect patterns of semaglutide and liraglutide for different uses based on safety report analysisIndication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis.

📖 Top 20% JournalArticle

3 weeks ago • Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Use of GLP-1 receptor drugs and complications after body shaping surgery after major weight lossGLP-1 receptor agonist use and postoperative complications after body contouring surgery following massive weight loss.

📖 Top 30% JournalArticle

3 weeks ago • North American Spine Society journal

Effects of GLP-1 receptor agonists on spine fusion success, safety, and risks in planned spine surgeryGLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.

📖 Top 20% JournalArticle

3 weeks ago • Acta neuropsychiatrica

Effects of GLP-1 single-acting drugs on reward processing in animal studiesEffects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic review.

📖 Top 20% JournalSystematic Review

3 weeks ago • Frontiers in cardiovascular medicine

📖 Top 20% JournalSystematic Review

3 weeks ago • Internal medicine (Tokyo, Japan)

Changes in Walking Speed Over 12 Months of Obesity Treatment with Semaglutide in Japanese Adults with Muscle and Joint ProblemsChanges in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.

Article

3 weeks ago • Drug design, development and therapy

Oral Obesity Drugs in Heart, Kidney, and Metabolic Conditions: Moving Beyond Weight Loss to Changing DiseaseOral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.

📖 Top 20% JournalArticle

3 weeks ago • Aesthetic surgery journal

Facial Changes Linked to Glucagon-Like Peptide-1 Receptor Agonists: Causes, Symptoms, Risks, Prevention, and TreatmentGlucagon-Like Peptide-1 Receptor Agonist-Associated Facial Changes: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Risk Factors, Prevention, and Management.

📖 Top 20% JournalArticle

3 weeks ago • Expert opinion on pharmacotherapy

Drug treatments for MASLD and MASH: approved options, reused medicines, and new targeted drugsPharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.

📖 Top 30% JournalArticle

3 weeks ago • Journal of diabetes and metabolic disorders

What adult weight-loss drugs can teach us about treating childhood obesityThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.

📖 Top 50% JournalArticle

3 weeks ago • European journal of pharmacology

Sitagliptin and GTS-21 together may improve blood sugar control and kidney damage by reducing cell death in diabetic miceEffects of sitagliptin combined with GTS-21 on improving glycemic control and diabetic nephropathy by anti-apoptosis in Leprdb/db mice.

📖 Top 20% JournalArticle

3 weeks ago • The FEBS journal

How different nutrients together trigger release of GLP-1 and nerve signals in gut hormone cellsNutrient-specific combinatorial secretion of GLP-1 and neurotransmitters in the enteroendocrine L-cell line GLUTag.

🥉 Top 5% JournalArticle

3 weeks ago • European journal of preventive cardiology

Health outcomes in people with diabetes, heart artery disease, and heart failure treated with tirzepatide or dulaglutideOutcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.

🥉 Top 5% JournalArticle

3 weeks ago • Acta diabetologica

Do GLP-1 receptor drugs cause hair loss, have no real effect, or might they help with it?GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?

Article

3 weeks ago • Journal of dental research

Potential Benefits and Challenges of GLP-1 Receptor Agonists in Dental CareGLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps.

Article

3 weeks ago • Expert opinion on pharmacotherapy

Obesity treatment with oral medication for people who avoid injectionsObesity: oral therapy for those afraid of needles.

📖 Top 30% JournalArticle

← prevpage 11 of 16next →

Latest GLP-1 Therapies Research Papers